The Experts below are selected from a list of 360 Experts worldwide ranked by ideXlab platform
Toshihiro Nishizawa - One of the best experts on this subject based on the ideXlab platform.
-
Rifabutin based 10 day and 14 day triple therapy as a third line and fourth line regimen for helicobacter pylori eradication a pilot study
United European gastroenterology journal, 2016Co-Authors: Hideki Mori, Hidekazu Suzuki, Juntaro Matsuzaki, Hitoshi Tsugawa, Kenro Hirata, Seiichiro Fukuhara, Sawako Miyoshi, Takashi Seino, Misako Matsushita, Toshihiro NishizawaAbstract:Background and aimThis prospective randomized study was designed to assess the efficacy of 10-day and 14-day Rifabutin-based triple therapy as a third- or fourth-line rescue therapy.MethodsPatients who failed first- and second-line eradication therapy were enrolled. H. pylori was isolated from gastric biopsy specimens and the rpoB mutation status, a factor of resistance to rifamycins, and minimum inhibitory concentrations (MICs) of Rifabutin and amoxicillin were determined. Enrolled patients were randomly assigned to receive 10-day or 14-day eradication therapy with esomeprazole (20 mg, 4 times a day (q.i.d.)), amoxicillin (500 mg, q.i.d.), and Rifabutin (300 mg, once a day (q.d.s.)). Poor compliance was defined as intake of <80% of study drugs. Successful H. pylori eradication was confirmed using a [13C] urea breath test or a stool antigen test, 12 weeks after the end of therapy.ResultsTwelve patients were assigned to the 10-day group, and 17, to the 14-day group. Intention-to-treat and per-protocol anal...
-
helicobacter pylori resistance to Rifabutin in the last 7 years
Antimicrobial Agents and Chemotherapy, 2011Co-Authors: Toshihiro Nishizawa, Hidekazu Suzuki, Juntaro Matsuzaki, Hiroe Muraoka, Hitoshi Tsugawa, Kenro Hirata, Toshifumi HibiAbstract:A low rate of resistance (0.24%) to Rifabutin was noted in Helicobacter pylori strains isolated from 414 Japanese patients. The only Rifabutin-resistant strain detected showed a point mutation in the rpoB gene and was isolated from a patient with a history of rifampin treatment for pulmonary tuberculosis.
-
past rifampicin dosing determines Rifabutin resistance of helicobacter pylori
Digestion, 2009Co-Authors: Shoji Suzuki, Toshihiro Nishizawa, Hidekazu Suzuki, Hiroe Muraoka, Fumihiko Kaneko, Sumire Ootani, Yoshimasa Saito, Intetsu Kobayashi, Toshifumi HibiAbstract:Background: Recently, the number of Helicobacter pylori isolates showing antibiotic resistance has been increasing. Rifabutin (RFB) is one of the possible candida
Javier P Gisbert - One of the best experts on this subject based on the ideXlab platform.
-
fourth line rescue therapy with Rifabutin in patients with three helicobacter pylori eradication failures
Alimentary Pharmacology & Therapeutics, 2012Co-Authors: Javier P Gisbert, Luis Rodrigo, Manuel Castrofernandez, Angeles Perezaisa, Angel Cosme, Javier Molinainfante, Ines Modolell, Jose Luis Cabriada, Joseluis Gisbert, Eloisa LamasAbstract:Summary Background In some cases, Helicobacter pylori infection persists even after three eradication treatments. Aim To evaluate the efficacy of an empirical fourth-line rescue regimen with Rifabutin in patients with three eradication failures. Methods Design: Multicentre, prospective study. Patients: In whom the following three treatments had consecutively failed: first (PPI + clarithromycin + amoxicillin); second (PPI + bismuth + tetracycline + metronidazole); third (PPI + amoxicillin + levofloxacin). Intervention: A fourth regimen with Rifabutin (150 mg b.d.), amoxicillin (1 g b.d.) and a PPI (standard dose b.d.) was prescribed for 10 days. Outcome: Eradication was confirmed by 13C-urea breath test 4–8 weeks after therapy. Compliance and tolerance: Compliance was determined through questioning and recovery of empty medication envelopes. Adverse effects were evaluated using a questionnaire. Results One-hundred patients (mean age 50 years, 39% men, 31% peptic ulcer/69% functional dyspepsia) were included. Eight patients did not take the medication correctly (in six cases due to adverse effects). Per-protocol and intention-to-treat eradication rates were 52% (95% CI = 41–63%) and 50% (40–60%). Adverse effects were reported in 30 (30%) patients: nausea/vomiting (13 patients), asthenia/anorexia (8), abdominal pain (7), diarrhoea (5), fever (4), metallic taste (4), myalgia (4), hypertransaminasemia (2), leucopenia (<1,500 neutrophils) (2), thrombopenia (<150 000 platelets) (2), headache (1) and aphthous stomatitis (1). Myelotoxicity resolved spontaneously in all cases. Conclusions Even after three previous H. pylori eradication failures, an empirical fourth-line rescue treatment with Rifabutin may be effective in approximately 50% of the cases. Therefore, Rifabutin-based rescue therapy constitutes a valid strategy after multiple previous eradication failures with key antibiotics, such as clarithromycin, metronidazole, tetracycline and levofloxacin.
-
review article Rifabutin in the treatment of refractory helicobacter pylori infection
Alimentary Pharmacology & Therapeutics, 2012Co-Authors: Javier P Gisbert, Xavier CalvetAbstract:Aliment Pharmacol Ther 2012; 35: 209–221 Summary Background Even with the current most effective treatment regimens, a relevant proportion of patients will fail to eradicate Helicobacter pylori infection. Aim To evaluate the role of Rifabutin in the treatment of H. pylori infection. Methods Bibliographical searches were performed in MEDLINE. Data on the efficacy of Rifabutin-containing regimens on H. pylori eradication were combined and meta-analysed using the generic inverse variance method. Results Rifabutin shows good in vitro activity against H. pylori. Mean H. pylori Rifabutin resistance rate (calculated from 11 studies including 2982 patients) was 1.3% (95% confidence interval = 0.9–1.7%). When only studies including patients naive to H. pylori eradication treatment were considered, this figure was even lower (0.6%). On the other hand, higher values of Rifabutin resistance were calculated (1.59%) when only post-treatment patients were considered. Overall, mean H. pylori eradication rate (intention-to-treat analysis) with Rifabutin-containing regimens (1008 patients) was 73% (67–79%). Respective cure rates for second-line (223 patients), third-line (342 patients) and fourth/fifth-line (95 patients) Rifabutin therapies were 79% (67–92%), 66% (55–77%) and 70% (60–79%) respectively. For treating H. pylori infection, almost all studies have administered Rifabutin 300 mg/day; this dose seems to be more effective than 150 mg/day. The ideal length of treatment remains unclear, but 10- to 12-day regimens are generally recommended. The mean rate of adverse effects was 22% (19–25%). Myelotoxicity is the most significant, although this complication was rare. Until now, all patients have recovered of leucopenia uneventfully in a few days, and there have been no reports of infection or other adverse outcomes related to it. Conclusion Rifabutin-containing rescue therapy constitutes an encouraging strategy after multiple (usually three) previous eradication failures with key antibiotics such as amoxicillin, clarithromycin, metronidazole, tetracycline and levofloxacin.
-
third line rescue therapy with levofloxacin is more effective than Rifabutin rescue regimen after two helicobacter pylori treatment failures
Alimentary Pharmacology & Therapeutics, 2006Co-Authors: Javier P Gisbert, Joseluis Gisbert, Santiago Marcos, R Morenootero, J M PajaresAbstract:Summary Background In patients with a first eradication failure, a second (rescue) therapy still fails in > 20% of cases. Aim To compare Rifabutin and levofloxacin rescue regimens in patients with two consecutive Helicobacter pylori eradication failures. Methods Patients, in whom first treatment with omeprazole–clarithromycin–amoxicillin and a second trial with omeprazole–bismuth–tetracycline–metronidazole (or ranitidine bismuth citrate with these antibiotics) had failed, received 10 days of treatment with either Rifabutin (150 mg b.d.) or levofloxacin (500 mg b.d.), plus amoxicillin (1 g b.d.) and omeprazole (20 mg b.d.). Cure rates were evaluated by the 13C-urea breath test. Results Twenty patients received Rifabutin, and 20 levofloxacin. All the patients returned for follow-up. Compliance in the Rifabutin group was 100%. Four patients in the levofloxacin group did not take the medication correctly (in two cases due to adverse effects: myalgia and rash). Side effects in the Rifabutin and levofloxacin groups were reported in 60% and 50% of the cases, respectively. Five patients (25%) treated with Rifabutin presented with leucopenia, and six (30%) treated with levofloxacin presented with myalgias. Per-protocol cure rates were 45% (95% confidence interval, 26–66%) in the Rifabutin group, and 81% (57–93%) in the levofloxacin group (P < 0.05). Intention-to-treat cure rates were, 45% (26–66%) and 85% (64–95%), respectively (P < 0.01). Conclusions After two previous H. pylori eradication failures, a 10-day triple levofloxacin-based rescue regimen is more effective than the same regimen with Rifabutin.
Robin Patel - One of the best experts on this subject based on the ideXlab platform.
-
in vitro activity of rifampin Rifabutin and rifapentine against enterococci and streptococci from periprosthetic joint infection
Microbiology spectrum, 2021Co-Authors: Mariana Albano, Melissa J Karau, Douglas R Osmon, Caitlin P Oravec, Daniel J Berry, Matthew P Abdel, Kerryl E Greenwoodquaintance, Robin PatelAbstract:After staphylococci, streptococci and enterococci are the most frequent causes of periprosthetic joint infection (PJI). MICs and minimum biofilm bactericidal concentrations of rifampin, Rifabutin, and rifapentine were determined for 67 enterococcal and 59 streptococcal PJI isolates. Eighty-eight isolates had rifampin MICs of ≤1 μg/ml, among which Rifabutin and rifapentine MICs were ≤ 8 and ≤4 μg/ml, respectively. There was low rifamycin in vitro antibiofilm activity except for a subset of Streptococcus mitis group isolates. IMPORTANCE Rifampin is an antibiotic with antistaphylococcal biofilm activity used in the management of staphylococcal periprosthetic joint infection with irrigation and debridement with component retention; some patients are unable to receive rifampin due to drug interactions or intolerance. We recently showed Rifabutin and rifapentine to have in vitro activity against planktonic and biofilm states of rifampin-susceptible periprosthetic joint infection-associated staphylococci. After staphylococci, streptococci and enterococci combined are the most common causes of periprosthetic joint infection. Here, we investigated the in vitro antibiofilm activity of rifampin, Rifabutin, and rifapentine against 126 Streptococcus and Enterococcus periprosthetic joint infection isolates. In contrast to our prior findings with staphylococcal biofilms, there was low antibiofilm activity of rifampin, Rifabutin, and rifapentine against PJI-associated streptococci and enterococci, apart from some Streptococcus mitis group isolates.
-
rifampin rifapentine and Rifabutin are active against intracellular periprosthetic joint infection associated staphylococcus epidermidis
Antimicrobial Agents and Chemotherapy, 2021Co-Authors: Cody Fisher, Robin PatelAbstract:Staphylococcus epidermidis is a major cause of periprosthetic joint infection (PJI); its intracellular persistence within osteoblasts may compromise therapy if that therapy is not intracellularly active. The intracellular activity of rifampin, rifapentine, and Rifabutin was assessed against five rifampin-susceptible and two rifampin-resistant S. epidermidis isolates. Compared to no treatment, treatment resulted in a ≥2-fold log10 reduction of intracellular rifampin-susceptible, but not rifampin-resistant S. epidermidis These findings show activity of rifampin, rifapentine, and Rifabutin against intra-osteoblast PJI-associated S. epidermidis.
Toshifumi Hibi - One of the best experts on this subject based on the ideXlab platform.
-
helicobacter pylori resistance to Rifabutin in the last 7 years
Antimicrobial Agents and Chemotherapy, 2011Co-Authors: Toshihiro Nishizawa, Hidekazu Suzuki, Juntaro Matsuzaki, Hiroe Muraoka, Hitoshi Tsugawa, Kenro Hirata, Toshifumi HibiAbstract:A low rate of resistance (0.24%) to Rifabutin was noted in Helicobacter pylori strains isolated from 414 Japanese patients. The only Rifabutin-resistant strain detected showed a point mutation in the rpoB gene and was isolated from a patient with a history of rifampin treatment for pulmonary tuberculosis.
-
past rifampicin dosing determines Rifabutin resistance of helicobacter pylori
Digestion, 2009Co-Authors: Shoji Suzuki, Toshihiro Nishizawa, Hidekazu Suzuki, Hiroe Muraoka, Fumihiko Kaneko, Sumire Ootani, Yoshimasa Saito, Intetsu Kobayashi, Toshifumi HibiAbstract:Background: Recently, the number of Helicobacter pylori isolates showing antibiotic resistance has been increasing. Rifabutin (RFB) is one of the possible candida
Hidekazu Suzuki - One of the best experts on this subject based on the ideXlab platform.
-
Rifabutin based 10 day and 14 day triple therapy as a third line and fourth line regimen for helicobacter pylori eradication a pilot study
United European gastroenterology journal, 2016Co-Authors: Hideki Mori, Hidekazu Suzuki, Juntaro Matsuzaki, Hitoshi Tsugawa, Kenro Hirata, Seiichiro Fukuhara, Sawako Miyoshi, Takashi Seino, Misako Matsushita, Toshihiro NishizawaAbstract:Background and aimThis prospective randomized study was designed to assess the efficacy of 10-day and 14-day Rifabutin-based triple therapy as a third- or fourth-line rescue therapy.MethodsPatients who failed first- and second-line eradication therapy were enrolled. H. pylori was isolated from gastric biopsy specimens and the rpoB mutation status, a factor of resistance to rifamycins, and minimum inhibitory concentrations (MICs) of Rifabutin and amoxicillin were determined. Enrolled patients were randomly assigned to receive 10-day or 14-day eradication therapy with esomeprazole (20 mg, 4 times a day (q.i.d.)), amoxicillin (500 mg, q.i.d.), and Rifabutin (300 mg, once a day (q.d.s.)). Poor compliance was defined as intake of <80% of study drugs. Successful H. pylori eradication was confirmed using a [13C] urea breath test or a stool antigen test, 12 weeks after the end of therapy.ResultsTwelve patients were assigned to the 10-day group, and 17, to the 14-day group. Intention-to-treat and per-protocol anal...
-
helicobacter pylori resistance to Rifabutin in the last 7 years
Antimicrobial Agents and Chemotherapy, 2011Co-Authors: Toshihiro Nishizawa, Hidekazu Suzuki, Juntaro Matsuzaki, Hiroe Muraoka, Hitoshi Tsugawa, Kenro Hirata, Toshifumi HibiAbstract:A low rate of resistance (0.24%) to Rifabutin was noted in Helicobacter pylori strains isolated from 414 Japanese patients. The only Rifabutin-resistant strain detected showed a point mutation in the rpoB gene and was isolated from a patient with a history of rifampin treatment for pulmonary tuberculosis.
-
past rifampicin dosing determines Rifabutin resistance of helicobacter pylori
Digestion, 2009Co-Authors: Shoji Suzuki, Toshihiro Nishizawa, Hidekazu Suzuki, Hiroe Muraoka, Fumihiko Kaneko, Sumire Ootani, Yoshimasa Saito, Intetsu Kobayashi, Toshifumi HibiAbstract:Background: Recently, the number of Helicobacter pylori isolates showing antibiotic resistance has been increasing. Rifabutin (RFB) is one of the possible candida
